科研之友
微信
新浪微博
Facebook
分享链接
摘要
Dolutegravir (DIG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DIG shows a limited cross-resistance profile. More interestingly, clinical resistance mutations to DIG in treatment-naive patents have not been observed to this date. This review summarizes recent studies on resistance mutations to DIG and on our understanding of the mechanisms of resistance to DIG as well as future directions for research.
- 出版日期2015-4-29
- 单位McGill; 河北医科大学
